IDEAYA Biosciences Inc
IDYAHealthcare|Biotechnology|USA
$36.99
-0.29 (-0.78%)
Tangible Book
$10.67
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07015190 Neoadjuvant Darovasertib in Primary Uveal Melanoma | Uveal Melanoma | P3 | Recruiting | 520 | RCT, Open-label | Darovasertib |
| NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | P2P3 | Active | 420 | RCT, Open-label | IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine |
| NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma, Cutaneous Melanoma | P1P2 | Recruiting | 336 | Open-label | IDE196, Binimetinib, Crizotinib |
| NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | Neoplasms, Colorectal, Solid Tumor | P1P2 | Active | 14 | Open-label | GSK4418959, PD-1 inhibitor |
| NCT07174583 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Small-cell Lung Cancer, Neuroendocrine Carcinomas | P1P2 | Recruiting | 262 | Open-label | IDE849, durvalumab, IDE161, Carboplatin |
| NCT05907954 (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Uveal Melanoma | P2 | Active | 160 | Open-label | Darovasertib |
| NCT07540572 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC) | P1 | Recruiting | 160 | Open-label | IDE574, Fulvestrant injection |
| NCT07277413 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | P1 | Recruiting | 260 | Open-label | IDE892, IDE397 |
| NCT04794699 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Solid Tumor | P1 | Active | 169 | Open-label | IDE397, Sacituzumab govitecan |
| NCT07503808 A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer | P1 | Recruiting | 150 | Open-label | IDE034 |
| NCT05787587 A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Advanced or Metastatic Solid Tumors, Breast Cancer | P1 | Active | 216 | Open-label | IDE-161, Pembrolizumab |